As of 2025-09-19, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is -0.62 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.50 CAD, the upside of Helix Biopharma Corp is -141.60%.
Based on its market price of 1.50 CAD and our intrinsic valuation, Helix Biopharma Corp (HBP.TO) is overvalued by 141.60%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.62 - -0.62 | -0.62 | -141.60% |
| P/E | (0.01) - (0.04) | (0.01) | -100.8% |
| DDM - Stable | (0.97) - (9.75) | (5.36) | -457.2% |
| DDM - Multi | (0.87) - (7.24) | (1.59) | -206.1% |
| Market Cap (mil) | 114.57 |
| Beta | 1.09 |
| Outstanding shares (mil) | 76.38 |
| Enterprise Value (mil) | 113.85 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.09% |
| Cost of Debt | 5.00% |
| WACC | 6.39% |